Is Valeant Pharmaceuticals Intl Inc a Buy? The Stock Had Bullish Options Activity Today

 Is Valeant Pharmaceuticals Intl Inc a Buy? The Stock Had Bullish Options Activity Today

In today’s session Valeant Pharmaceuticals Intl Inc (VRX) registered an unusually high (917) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious VRX increase. With 917 contracts traded and 214254 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: VRX170120C00050000 closed last at: $0.27 or 22.7% up. About 6.12M shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 67.87% since March 14, 2016 and is downtrending. It has underperformed by 73.49% the S&P500.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage

Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 9 rate it a “Buy”, 2 “Sell”, while 12 “Hold”. This means 39% are positive. Valeant Pharmaceuticals Intl has been the topic of 75 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The rating was maintained by JP Morgan on Wednesday, March 16 with “Overweight”. The rating was maintained by Stifel Nicolaus on Wednesday, November 11 with “Buy”. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Buy” rating by Jefferies on Monday, November 2. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Neutral” rating given on Wednesday, March 16 by Nomura. The stock has “Buy” rating given by Rodman & Renshaw on Wednesday, March 16. The firm has “Neutral” rating by Mizuho given on Tuesday, March 8. The firm has “Buy” rating given on Wednesday, June 8 by Stifel Nicolaus. Guggenheim maintained the stock with “Buy” rating in Friday, November 6 report. The company was maintained on Wednesday, November 11 by JP Morgan. As per Wednesday, March 16, the company rating was maintained by Morgan Stanley.

According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”

Insitutional Activity: The institutional sentiment decreased to 0.86 in 2016 Q2. Its down 0.06, from 0.92 in 2016Q1. The ratio dived, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Nomura, a Japan-based fund reported 6.57 million shares. Connor Clark & Lunn Inv Mgmt owns 1.89M shares or 0.28% of their US portfolio. Hbk Invs L P owns 653,353 shares or 0.11% of their US portfolio. Glenhill Advsr Ltd Limited Liability Company last reported 3.28% of its portfolio in the stock. Cohen Klingenstein Llc, a New York-based fund reported 16,738 shares. Alpine Prtnrs Vi Lc last reported 20,000 shares in the company. Twin Tree Mngmt L P accumulated 0% or 4,000 shares. Moreover, Stanley Capital Mngmt Ltd Liability Co has 1.17% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 57,800 shares. Axa holds 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 11,541 shares. Credit Agricole S A last reported 0.02% of its portfolio in the stock. Teewinot Advisers Ltd Llc, a New York-based fund reported 50,100 shares. Tru Of Vermont has 2,000 shares for 0.01% of their US portfolio. Redwood Cap Mngmt Limited Com, a New Jersey-based fund reported 150,000 shares. Marathon Trading Invest Ltd last reported 0.1% of its portfolio in the stock. Hsbc Pcl has invested 0.02% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Insider Transactions: Since June 9, 2016, the stock had 2 buys, and 0 selling transactions for $5.04 million net activity. 4,000 Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares with value of $98,600 were bought by KARABELAS ARGERIS N. PAPA JOSEPH C bought 202,000 shares worth $4.94 million.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $7.27 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Fool.com which released: “These 2 Factors Pushed Valeant Pharmaceuticals Intl. Inc. Down 15% in September” on October 07, 2016, also Fool.com with their article: “Better Buy: Valeant Pharmaceuticals International, Inc. vs. Endo International plc” published on September 30, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: VRX Stock to Regain Value?” on September 27, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Investorplace.com and their article: “2 Ways to Make Bank on Valeant Pharmaceuticals Intl Inc (VRX)” published on October 10, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Stock: Many Are Bullish on Valeant Pharmaceuticals Intl Inc” with publication date: September 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment